CLINICAL ROLE -
What’s Ahead in the Adalimumab Biosimilar Pipeline in Dermatology
FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
HSSP Leads to High Rate of Acid Suppression Therapy Substitution
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.
2 Commerce Drive Cranbury, NJ 08512